-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Clinical data from a self-controlled trial of the safety and efficacy of a treatment of refractory children with systemic lupus erythematosus (cSLE) in a titazep, published in the journal Lupus
.
Results showed that 15 patients with refractory cSLE had a 66.
The combination of tetazeptide and standard therapy can significantly improve the SRI-4 response rate in children with SLE, reduce the dose of glucocorticoids in patients with refractory cSLE, and have efficacy
in lupus nephritis.
In 15 children with refractory lupus erythematosus, disease activity improved or controlled in a relatively short period of time after the use of tetazep, and the dose of the hormone could be rapidly reduced or increased
again.
Because of its convenient use, few short-term side effects, and certain efficacy, tytazeptide shows certain advantages in children with refractory SLE, and its long-term side effects and efficacy are continuously observed
.
About Taytsip
Tytasip is the antibody fusion protein drug molecule invented and designed by Professor Jianmin, CEO of Rongchang Bio and Chief Scientific Official
.
Internationally, a U.
Original Source:
Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H.